![An employee works on a production line at the factory of British multinational pharmaceutical company GlaxoSmithKline (GSK) in Saint-Amand-les-Eaux, northern France, on December 3, 2020, where the adjuvant for Covid-19 vaccines will be manufactured. Canada's Medicago and British pharmaceutical giant GlaxoSmithKline (GSK) announced on December 3, 2020 the launch of phase 2 and 3 clinical trials on a Covid-19 vaccine, one of a series of candidates being developed worldwide. Final phase 3 trials of the plant-derived vaccine candidate will begin by year's end and will be tested on 30,000 volunteers in North America, Latin America and Europe, according to a joint statement.
/ AFP / FRANCOIS LO PRESTI](https://thenational-the-national-prod.cdn.arcpublishing.com/resizer/v2/7GYSYV62L3DGVN5LQWYVYCXDJQ.jpg?smart=true&auth=8b10549ef6d02945b56c91115550b7b0d4d7b595c905fc68bd7a558e5dc9fc4f&width=400&height=225)
GlaxoSmithKline and partner Sanofi have delayed the release of their vaccine by a year. AFP
GlaxoSmithKline and partner Sanofi have delayed the release of their vaccine by a year. AFP
Blow to vaccine hopes as British-French partnership delays release of shot by a year
Trials showed the GlaxoSmithKline-Sanofi vaccine did not protect older people